AstraZeneca

AstraZeneca and Amgen's Phase III trial of Tezspire showed significant reduction in nasal polyp size and congestion in chronic rhinosinusitis with nasal polyps patients, offering a new treatment option.

Daiichi Sankyo and AstraZeneca awarded 2024 Prix Galien USA for ENHERTU, a HER2-directed ADC, at American Museum of Natural History in New York.

AstraZeneca and Amgen's Tezspire met co-primary endpoints in a Phase III trial for chronic rhinosinusitis with nasal polyps, showing significant reduction in nasal polyps and congestion. Tezspire, a TSLP inhibiting monoclonal antibody, also received FDA breakthrough therapy designation for COPD. The therapy competes with Sanofi and Regeneron's Dupixent, which generated €10.7bn in sales in 2022. Both Tezspire and Dupixent are projected to see increased sales by 2030.

Beam Therapeutics acknowledges a patient death in a Phase 1/2 trial for sickle cell disease, attributing it to pre-conditioning, not the base-editing treatment. AstraZeneca, UT, and LIVESTRONG report successful therapeutic genome editing in mouse liver via lipid nanoparticles. Korean researchers find base and prime editors produce fewer large DNA deletions than Cas9 nucleases. YolTech demonstrates effective mRNA delivery to bone marrow cells for blood disorder treatment. Japanese scientists develop a curative strategy for congenital purpura fulminans using engineered APC. US-France team identifies key host factors enhancing rotavirus vaccine production. Allogene Therapeutics shares positive Phase 1 data for renal cell carcinoma treatment. Cellectis presents strategies to enhance CAR T-cell efficacy in solid tumors. Caszyme and Integra Therapeutics enter a licensing agreement for safer gene therapies. Industry updates include financial results and clinical trial progress from various companies. CRISPR genome engineering symposium to feature latest advancements. CRISPR gene editing can integrate mitochondrial DNA into the nuclear genome, but exonucleases can mitigate this. HuidaGene Therapeutics' CRISPR-Cas13 RNA-editing therapy for macular degeneration is accepted by the FDA.

TEZSPIRE (tezepelumab) showed significant reduction in nasal polyp size and nasal congestion in Phase III WAYPOINT trial for chronic rhinosinusitis with nasal polyps (CRSwNP), compared to placebo.

CervoMed Inc. wins Prix Galien USA 2024 Best Startup award for developing potential treatment for Dementia with Lewy bodies (DLB), a condition affecting over 1.4 million patients in the U.S. and EU. The company's drug, neflamapimod, is in Phase 2b clinical trial, with topline results expected in December 2024.

Experts discuss tirzepatide's safety and benefits after a UK death linked to the drug, highlighting the need for high-quality trials and the importance of the 'yellow card scheme' for reporting side effects.

FTSE 100 futures up 12.50 points to 8,185.0. IAG's Q3 revenue rose 7.9% to €9.33bn, with 15.4% operating profit jump to €2.01bn. AstraZeneca's Texspire phase III trial showed significant nasal polyp reduction. Oaktree Capital urges Indivior board refresh for shareholder value. Health groups call for salt and sugar taxes. AI could displace 1-3m UK private sector jobs. Bentley delays full electrification to 2035. US markets mixed post-Trump victory and Fed rate decision.